- The Wall Street Journal•3 hours ago
Regeneron Pharmaceuticals and Sanofi said they will charge $37,000 annually in the U.S. for their newly approved eczema drug, a price the companies said they reached after months of negotiations with pharmacy ...
- American City Business Journals•10 hours ago
The FDA has approved a drug to treat eczema made by Cambridge-based Sanofi Genzyme that some analysts believe could eventually surpass $3 billion in annual sales. The agency announced Tuesday that it has approved dupilumab, a treatment for atopic dermatitis that will be sold under the brand name Dupixent. The drug was developed by Sanofi Genzyme, a division of French pharmaceutical giant Sanofi SA (SNY), along with its partner Regeneron Pharmaceuticals (REGN).
- Investor's Business Daily•11 hours ago
Regeneron and Sanofi will price eczema drug Dupixent at $37,000 annually, the companies said Tuesday.
SAN.PA : Summary for SANOFI - Yahoo Finance
Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||84.00 - 84.61|
|52 Week Range||62.50 - 84.61|
|PE Ratio (TTM)||23.25|
|Dividend & Yield||3.35 (3.68%)|
|1y Target Est||N/A|